Valneva Reports Half Year 2023 Financial Results and Provides Corporate Updates

Product sales more than doubled in the first half of 2023 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO® and DUKORAL® sales, both of which benefited from a continued

Related Keywords

Canada ,France ,United Kingdom ,Solna ,Stockholm ,Sweden ,Japan ,Australia ,Brazil ,New Zealand ,United States ,Thailand ,Switzerland ,Japanese ,Swedish ,America ,Instituto Butantan ,Deerfield Orbimed ,European Medicines Agency ,Us Defense Logistics Agency ,Drug Administration ,European Union ,Us Department Of Defense Do ,Pfizer ,Coalition For Epidemic Preparedness Innovations ,Health Canada ,Third Party ,Pan American Health Organization ,European Union Horizon ,Funds Deerfield ,License Application ,Financial Reports ,Chief Financial Officer ,Biologic License Application ,Prescription Drug User Fee Act ,Lancet Infectious Diseases ,Epidemic Preparedness Innovations ,Middle Income Countries ,Breakthrough Therapy ,Priority Review ,Priority Review Voucher ,North America ,Fast Track ,Against Lyme ,Outdoor Recreationists ,Good Clinical Practice ,Marketing Authorization Application ,Southeast Asia ,Pacific Islands ,Japanese Encephalitis ,Target Product Profile ,Logistics Agency ,Management Board ,Northx Biologics ,Valneva Sweden ,Bavarian Nordic ,Scottish Enterprise ,Zine Analytics Chikungunya ,